Certara Inc (CERT)
$11.60 $0.10 (0.87%) 4:37 PM 12/10/24
NASDAQ | $USD | Health Information ServicesStock Data
-
Market Cap
$1.75B -
Day's Range
$11.32 - $11.67 -
Volume
1,440,614 -
52 Week Low / High
$9.41 - $19.87 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 4
- Strong Buy
- 0
- Buy
- 7
- Hold
- 0
- Sell
- 0
- Strong Sell
- $18.57
- Target Price
Company News
-
High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024
In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...
-
Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024
Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...
-
Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024
Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024
Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...
-
Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024
Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...
-
Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024
Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...
-
Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024
Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...
-
Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024
Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...
-
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024
Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024
In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...
-
Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024
Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...
-
Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024
Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...
-
Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024
Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024
Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...
-
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024
Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...
-
High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024
In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...
-
High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024
In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...
-
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024
Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...
-
High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024
In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...
-
Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024
Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...
-
High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024
In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...
-
Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024
Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...
-
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024
Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024
Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024
Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...
-
Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024
Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...
-
Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024
Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...
-
Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024
Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...
-
Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024
Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024
Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...
-
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024
Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...
-
High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024
In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...
Portfolio
Comprised of 1 portfolios